Litigation Details for ModernaTX, Inc. v. Pfizer Inc. (D. Mass. 2022)

ModernaTX, Inc. v. Pfizer Inc. (D. Mass. 2022)

Docket		Date Filed	2022-08-26
Court	District Court, D. Massachusetts	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gaylore Stearns
Jury Demand	Both	Referred To
Patents	9,056,052; 9,061,005
Link to Docket	External link to docket

Details for ModernaTX, Inc. v. Pfizer Inc. (D. Mass. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-08-26				External link to document

Litigation summary and analysis for: ModernaTX, Inc. v. Pfizer Inc. (D. Mass. 2022)

Last updated: July 30, 2026

Moderna v. Pfizer 1:22-cv-11378: Litigation Summary, Claims, and Practical IP Impact

ModernaTX, Inc. v. Pfizer Inc. (D. Mass., Case No. 1:22-cv-11378) is a U.S. patent lawsuit filed in 2022 involving mRNA-related intellectual property asserted by Moderna against Pfizer. The case is in the federal litigation track where patent infringement, validity, and remedy issues are litigated under the Hatch-Waxman and general patent statutes, with potential downstream effects on commercialization timelines for Pfizer’s COVID-19 and pipeline mRNA programs.

What is ModernaTX, Inc. v. Pfizer Inc. 1:22-cv-11378 about?

Short answer: A patent infringement case brought by ModernaTX against Pfizer in the District of Massachusetts, alleging Pfizer infringes one or more Moderna patents relating to mRNA therapeutics or delivery and manufacturing approaches.

Court, docket, and procedural posture

• Case: ModernaTX, Inc. v. Pfizer Inc.
• Court: U.S. District Court for the District of Massachusetts
• Docket: 1:22-cv-11378
• Filed: 2022 (case number indicates late-2022 filing; exact filing date required for pinpoint accuracy)
• Forum significance: District of Massachusetts is a major venue for complex pharma patent disputes and frequently handles mRNA/IP cases, with fast-track scheduling and extensive claim-construction activity.

What claims are typically at issue in this type of Moderna-mRNA dispute

In Moderna-vs-Pfizer mRNA litigation, disputes usually center on:

• mRNA composition and sequence features (including untranslated region architecture, codon usage, and nucleoside modifications)
• formulation and delivery (lipid nanoparticle composition, charge balance, and particle properties)
• manufacturing methods (in vitro transcription conditions, purification steps, and quality attributes)
• use claims (therapeutic administration for prevention or treatment of disease, and patient dosing regimens)

Which patents are asserted in ModernaTX v. Pfizer 1:22-cv-11378?

Short answer: The specific asserted patent numbers and claim groupings determine both the scope of the infringement theory and the validity attack surface.

Why asserted patents matter for litigation outcomes

For mRNA technology disputes, each patent category drives different legal and technical outcomes:

• Composition/sequence patents tend to trigger defenses on design-around (different sequence features or UTR choices)
• LNP formulation patents often require granular comparisons of lipid blends and process conditions
• Manufacturing method patents usually pivot on process discovery and expert testimony tied to batch records
• Use patents raise inducement and direct infringement issues tied to label, sales, and instructions for use

What you can rely on for business triage

• In Moderna-style mRNA estates, multiple families often assert similar concepts across composition, formulation, and methods.
• Courts in the District of Massachusetts commonly conduct claim construction early, then resolve summary judgment on noninfringement/invalidity if the record is developed.

What is the strongest infringement theory likely in a ModernaTX vs. Pfizer mRNA case?

Short answer: Moderna’s strongest technical path in this category is usually infringement via Pfizer’s commercial mRNA products and any closely related internal development products, mapped to specific claim elements for mRNA structure, LNP formulation, and key process steps.

Direct infringement vs. inducement risk

• Direct infringement: Pfizer’s own manufacture, sale, and use of products in the U.S. can support direct infringement.
• Inducement and willful infringement: Moderna may argue Pfizer knowingly encourages infringement through manufacturing disclosures, regulatory filings, and product instructions.

Design-around exposure

Pfizer’s risk increases if the asserted claims cover:

• broad LNP composition ranges without strict lipid identity requirements
• sequence features that remain constant across variants and updated formulations
• general manufacturing steps that are hard to change without affecting product performance

How does claim construction affect ModernaTX v. Pfizer outcomes?

Short answer: Claim construction is usually the gating issue. If the court narrows claim terms to require specific sequence or formulation properties, Pfizer’s noninfringement chances improve. If the court adopts broader claim interpretations, Moderna’s infringement case strengthens.

Typical claim-construction disputes in mRNA/IP cases

Courts often fight over:

• definitions for mRNA “modifications” and what nucleoside substitutions count
• what constitutes an LNP “comprising” certain lipids and whether range limitations are strict or permissive
• whether a manufacturing step is “performed” under the claims when performed upstream by a contract manufacturer
• whether product attributes (particle size, encapsulation efficiency, polydispersity) are required as structural limitations

When does ModernaTX v. Pfizer 1:22-cv-11378 threaten Pfizer sales or product launches?

Short answer: The litigation threat level depends on (1) whether a preliminary injunction is sought, and (2) whether any asserted patents cover current commercial products or imminent launches.

Injunctive relief and business impact

• Patent suits can drive settlement leverage through risk of exclusion or injunction.
• Even without a preliminary injunction, the discovery burden and damages exposure can force cross-licensing or design-around acceleration.

Regulatory pathway interaction

If the case touches COVID-19 mRNA products, the FDA regulatory posture (supplement approvals for variant formulations) can influence whether Pfizer is forced to change formulation attributes covered by claims.

What defenses does Pfizer typically raise in Moderna mRNA patent cases?

Short answer: Pfizer’s standard playbook includes noninfringement, invalidity (anticipation/obviousness), and procedural defenses aimed at narrowing the patent estate.

Noninfringement mechanics

• element-by-element claim charts against Pfizer’s disclosed compositions and manufacturing parameters
• expert testimony comparing particle properties and nucleoside/UTR features

Invalidity mechanics

• prior art references from academic publications, PCT filings, and earlier patent publications
• obviousness combinations tied to lipid nanoparticles and modified mRNA delivery
• written description and enablement challenges, if the asserted claims broaden beyond the specification

Prosecution history and estoppel

Claim narrowing during prosecution can restrict Moderna’s ability to argue broad equivalents. Pfizer often relies on:

• disclaimer in prosecution
• arguments made in earlier cases involving similar Moderna patents

Has ModernaTX v. Pfizer 1:22-cv-11378 been stayed, settled, or resolved?

Short answer: A precise resolution status requires docket-level reading (orders, stipulations, and any settlement documents).

What to track for case momentum

Business-relevant milestone markers include:

• initial disclosures and infringement/validity content schedules
• claim construction order issuance
• discovery completion and summary judgment rulings
• trial scheduling or dismissal without prejudice

What patent settlement terms typically emerge in Moderna vs. Pfizer mRNA cases?

Short answer: Settlements in high-stakes mRNA patent disputes often take the form of cross-licenses, field-of-use limitations, and covenants not to sue, sometimes coupled with royalty structures or running licenses triggered by future product approvals.

Settlement term patterns that matter commercially

• scope limited by “products” defined by LNP composition, therapeutic indication, or manufacturing method
• carve-outs for R&D activities vs. commercial sales
• survival clauses addressing ongoing damages and litigation costs
• dismissal with prejudice once payments or licenses become effective

How many patents are likely in the asserted estate and how broad is the coverage?

Short answer: Moderna mRNA portfolios typically span multiple overlapping families across composition, formulation, and manufacturing. In any given dispute, the number of asserted patents can range from a few to several dozen depending on related families.

What “breadth” looks like in this technology space

• broad claim language on LNP lipid classes and functional ranges
• broad mRNA structural feature definitions (UTR and coding region architecture)
• process claims that cover generic lab steps tied to mRNA synthesis and purification

What is the commercial exposure for Pfizer if ModernaTX prevails?

Short answer: Exposure is highest when asserted claims map directly to commercial product manufacture and sales, and when damages can be calculated back to the effective infringement period.

Damages framework relevant to Pfizer

• reasonable royalty theories based on market rates or comparable licensing
• lost profits only if Moderna can show it would have sold the patented technology absent infringement (often fact-intensive)
• enhanced damages risk depends on willfulness proof and litigation conduct

How does ModernaTX v. Pfizer compare with other Moderna IP disputes?

Short answer: The core issue pattern mirrors other Moderna mRNA patent fights: Moderna alleges Pfizer uses protected mRNA or delivery approaches, Pfizer challenges claim scope and validity using prior art and noninfringement evidence.

Strategic comparison dimensions

• asserted claim categories (composition vs. formulation vs. manufacturing)
• speed and aggressiveness of claim construction
• whether Pfizer can show meaningful design-around changes between product generations
• whether the court narrows claims enough to defeat infringement

Key litigation checklist for business teams watching 1:22-cv-11378

• Claim construction: did the court narrow terms on sequence, modification, or LNP composition?
• Infringement mapping: did Moderna’s experts align claim elements to Pfizer production parameters?
• Validity posture: were any claims invalidated on anticipation or obviousness?
• Product scope: are the asserted patents tied to Pfizer’s current sales or variant-updated formulations?
• Injunction risk: did Moderna seek immediate injunctive relief, and has the court ruled on it?
• Settlement signals: docket entries indicating mediation, stipulations, or joint status reports.

---

Key Takeaways

1. ModernaTX, Inc. v. Pfizer Inc. (D. Mass. 1:22-cv-11378) is an mRNA-focused patent infringement dispute where the decisive driver is usually claim construction of mRNA, LNP, or manufacturing limitations.
2. Pfizer’s main risk is coverage breadth across commercial products plus difficulty proving noninfringement element-by-element.
3. The litigation’s commercial effect hinges on whether asserted patents track current Pfizer mRNA formulations and whether any narrowed claim constructions preserve infringement scope.
4. The most business-relevant milestones are claim construction outcomes, noninfringement/invalidity rulings, and any settlement or dismissal entries.

---

FAQs

1. What types of mRNA patents are most often asserted by Moderna in disputes with other large pharma companies?
2. How do courts in the District of Massachusetts handle claim construction for LNP composition and mRNA modification terms?
3. What evidence typically drives infringement findings for mRNA-LNP patents, batch records or regulatory disclosures?
4. When can mRNA patent litigation affect FDA supplement approval timing for updated formulations?
5. How do design-around changes in LNP lipid blends impact noninfringement arguments in mRNA cases?

---

References

1. PACER docket for ModernaTX, Inc. v. Pfizer Inc., No. 1:22-cv-11378 (D. Mass.).